The Copper Reduction Potential Determines the Reductive Cytotoxicity: Relevance to the Design of Metal–Organic Antitumor Drugs
Molecules · 2024
DOI: 10.3390/molecules29051032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Elena K Beloglazkina und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Lomonosov Moscow State University, 1/3 Leninskie Gory, Moscow 119991, Russia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Coordination Complexes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Foundation for Basic Research.
Abstract (Originalsprache)
Copper–organic compounds have gained momentum as potent antitumor drug candidates largely due to their ability to generate an oxidative burst upon the transition of Cu2+ to Cu1+ triggered by the exogenous-reducing agents. We have reported the differential potencies of a series of Cu(II)–organic complexes that produce reactive oxygen species (ROS) and cell death after incubation with N-acetylcysteine (NAC). To get insight into the structural prerequisites for optimization of the organic ligands, we herein investigated the electrochemical properties and the cytotoxicity of Cu(II) complexes with pyridylmethylenethiohydantoins, pyridylbenzothiazole, pyridylbenzimidazole, thiosemicarbazones and porphyrins. We demonstrate that the ability of the complexes to kill cells in combination with NAC is determined by the potential of the Cu+2 → Cu+1 redox transition rather than by the spatial structure of the organic ligand. For cell sensitization to the copper–organic complex, the electrochemical potential of the metal reduction should be lower than the oxidation potential of the reducing agent. Generally, the structural optimization of copper–organic complexes for combinations with the reducing agents should include uncharged organic ligands that carry hard electronegative inorganic moieties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Lomonosov Moscow State University, 1/3 Leninskie Gory, Moscow 119991, Russia.
- International Institute of Solution Chemistry and Advanced Materials and Technologies, ITMO University, 9 Lomonosov Street, Saint-Petersburg 197101, Russia.
- Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, 29 Leninsky Avenue, Moscow 119991, Russia.
- A.N.Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Bld. 1, 28 Vavilov Street, Moscow 119334, Russia.
- Blokhin National Medical Research Center of Oncology, 24 Kashirskoye Shosse, Moscow 115522, Russia.
ORCID-Profile: Elena K Beloglazkina, Sergey A Tsymbal, Dmitry A Guk, Olga O Krasnovskaya, Victoria M Alpatova, Andrei V Zaitsev, Alexander V Finko
Förderung
- Russian Foundation for Basic Research
Zitieren
APA
Beloglazkina, E. K., Moiseeva, A. A., Tsymbal, S. A., Guk, D. A., Kuzmin, M. A., Krasnovskaya, O. O., Borisov, R. S., Barskaya, E. S., Tafeenko, V. A., Alpatova, V. M., Zaitsev, A. V., Finko, A. V., Ol'shevskaya, V. A., & Shtil, A. A. (2024). The Copper Reduction Potential Determines the Reductive Cytotoxicity: Relevance to the Design of Metal–Organic Antitumor Drugs. Molecules. https://doi.org/10.3390/molecules29051032
Vancouver
Beloglazkina EK, Moiseeva AA, Tsymbal SA, Guk DA, Kuzmin MA, Krasnovskaya OO, et al. The Copper Reduction Potential Determines the Reductive Cytotoxicity: Relevance to the Design of Metal–Organic Antitumor Drugs. Molecules. 2024. doi:10.3390/molecules29051032
BibTeX
@article{Beloglazkina2024,
author = {Beloglazkina, Elena K and Moiseeva, Anna A and Tsymbal, Sergey A and Guk, Dmitry A and Kuzmin, Mikhail A and Krasnovskaya, Olga O and Borisov, Roman S and Barskaya, Elena S and Tafeenko, Victor A and Alpatova, Victoria M and Zaitsev, Andrei V and Finko, Alexander V and Ol'shevskaya, Valentina A and Shtil, Alexander A},
title = {The Copper Reduction Potential Determines the Reductive Cytotoxicity: Relevance to the Design of Metal–Organic Antitumor Drugs},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29051032}
}
EUVIMED